ACET (STOCKS)
Adicet Bio, Inc. Common Stock
$6.715000
-0.415000 (-5.82%)
Prev close: $7.130000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Chen Schor
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $65.23M
- Employees
- 152
- P/E (TTM)
- -0.35
- P/B (TTM)
- 0.34
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-4.64 | $-4.73 | +0.0881 | +1.86% |
|
Jun 2025 (Q2)
|
$-5.44 | $-4.97 | -0.4740 | -9.54% |
|
Mar 2025 (Q1)
|
$-4.96 | $-5.41 | +0.4529 | +8.37% |
|
Dec 2024 (Q4)
|
$-0.32 | $-0.37 | +0.0494 | +13.37% |
Financial Statements
| Revenues | $682.93M |
| Benefits Costs and Expenses | $822.94M |
| Cost Of Revenue | $595.79M |
| Costs And Expenses | $822.94M |
| Gross Profit | $87.14M |
| Nonoperating Income/Loss | -$20.98M |
| Operating Expenses | $410.43M |
| Selling, General, and Administrative Expenses | $137.06M |
| Depreciation and Amortization | $32.43M |
| Research and Development | $8.19M |
| Operating Income/Loss | -$314.38M |
| Income/Loss Before Equity Method Investments | -$337.93M |
| Income/Loss From Continuing Operations After Tax | -$346.15M |
| Income/Loss From Continuing Operations Before Tax | -$140.01M |
| Income/Loss From Equity Method Investments | $2.56M |
| Income Tax Expense/Benefit | $10.79M |
| Income Tax Expense/Benefit, Deferred | $8.96M |
| Interest Expense, Operating | $24.16M |
| Net Income/Loss | -$346.15M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$346.15M |
| Net Income/Loss Available To Common Stockholders, Basic | -$346.15M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$9.80 |
| Diluted Earnings Per Share | -$9.79 |
| Basic Average Shares | 70,898,000 |
| Diluted Average Shares | 70,898,000 |
| Assets | $753.16M |
| Current Assets | $504.69M |
| Inventory | $184.31M |
| Other Current Assets | $320.38M |
| Noncurrent Assets | $248.47M |
| Fixed Assets | $13.27M |
| Intangible Assets | $221.04M |
| Other Non-current Assets | $14.17M |
| Liabilities | $702.85M |
| Current Liabilities | $503.73M |
| Accounts Payable | $132.38M |
| Other Current Liabilities | $371.36M |
| Noncurrent Liabilities | $199.11M |
| Long-term Debt | $317.12M |
| Equity | $50.31M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $50.31M |
| Liabilities And Equity | $753.16M |
| Net Cash Flow From Operating Activities | $402.00K |
| Net Cash Flow From Operating Activities, Continuing | $402.00K |
| Net Cash Flow From Investing Activities | -$3.38M |
| Net Cash Flow From Investing Activities, Continuing | -$3.38M |
| Net Cash Flow From Financing Activities | -$19.12M |
| Net Cash Flow From Financing Activities, Continuing | -$19.12M |
| Exchange Gains/Losses | -$1.05M |
| Net Cash Flow | -$23.15M |
| Net Cash Flow, Continuing | -$22.10M |
| Comprehensive Income/Loss | -$347.91M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$273.48M |
| Other Comprehensive Income/Loss | -$45.20M |